Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) EPS (Basic) (2022 - 2026)

Indivior Pharmaceuticals has reported EPS (Basic) over the past 5 years, most recently at $0.71 for Q1 2026.

  • For Q1 2026, EPS (Basic) rose 86.84% year-over-year to $0.71; the TTM value through Mar 2026 reached $2.01, up 10150.0%, while the annual FY2025 figure was $1.68, 3260.0% up from the prior year.
  • EPS (Basic) for Q1 2026 was $0.71 at Indivior Pharmaceuticals, down from $0.81 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $225000.0 in Q1 2023 and troughed at -$231632.7 in Q3 2023.
  • A 5-year average of $19543.2 and a median of $0.42 in 2024 define the central range for EPS (Basic).
  • Biggest five-year swings in EPS (Basic): tumbled 421.52% in 2023 and later surged 406.25% in 2025.
  • Year by year, EPS (Basic) stood at -$2.37 in 2022, then surged by 120.97% to $0.5 in 2023, then tumbled by 67.76% to $0.16 in 2024, then surged by 406.25% to $0.81 in 2025, then dropped by 12.35% to $0.71 in 2026.
  • Business Quant data shows EPS (Basic) for INDV at $0.71 in Q1 2026, $0.81 in Q4 2025, and $0.34 in Q3 2025.